An emerging example of this important parallel is ACE2 pathway drugs (ACE inhibitors and angiotensin receptor blocking drugs), which are increasingly observed in humans with COVID-19 to be associated with improved survival advantage [158,159,160,161,162]. This evidence concerns the gene ACE2 and COVID-19.